Search Results
Your search for 3 matches 16011 pages
Showing 51 - 100Mammography Screening for Recurrence After a Diagnosis of Breast Cancer
Nahleh and colleagues recently updated ASCO guidelines regarding the frequency of breast screening following a diagnosis of primary breast cancer and recommended annual mammography for most patients.1 Presumably, the benefit of mammography will come from finding recurrences earlier, e.g., smaller...
ASCO Issues Its First Living Guideline on Systemic Treatment of Recurrent Ovarian Cancer
In June 2026, an ASCO Expert Panel voted to approve ASCO’s first Living Guideline on systemic treatment of ovarian cancer recurrence.1 The continuously updated, evidence-based guideline addresses patients with epithelial ovarian cancer, primary peritoneal carcinoma, and fallopian tube carcinoma,...
Data From Pivotal Trials Lead to Recent Drug Approvals in Colorectal, Breast, RCC, and CLL/SLL Malignancies
In September and October, the U.S. Food and Drug Administration (FDA) released statements regarding the Agency’s approval of a number of oncology drug products across several solid tumors and hematologic malignancies. A summary of these approvals is provided here. Combination Approved in dMMR Colon ...
Metastasis-Directed Ablation Does Not Improve Survival Outcomes in Oligometastatic Breast Cancer
The addition of metastasis-directed ablation to first-line systemic therapy did not significantly improve progression-free or overall survival in patients with oligometastatic breast cancer, according to findings from the randomized phase II portion of the NRG-BR002 trial reported by Chmura et al...
Phase III RT CHARM Trial Supports Shorter Postmastectomy Radiation Therapy After Breast Reconstruction
A shorter course of postmastectomy radiation therapy was noninferior to conventional radiation therapy in terms of breast reconstruction complications among women with breast cancer undergoing the procedure, according to findings from the randomized RT CHARM trial reported by Poppe et al in the...
Experts Call for Better Quality-of-Life Reporting in Adjuvant Cancer Trials
Clinical trials of adjuvant cancer therapy should do a better job of showing how treatment affects individual patients’ quality of life—particularly when the survival benefit is modest—according to recommendations from Common-Sense Oncology and the European Organisation for Research and Treatment...
Bivalent CAR T-Cell Therapy Shows Shows Durable Activity and Manageable Safety in Recurrent Glioblastoma
Longer follow-up from a phase I trial of intracerebroventricular bivalent CAR T-cell therapy in recurrent glioblastoma showed no long-term or delayed-onset toxicities, with a median overall survival of 12.0 months, according to updated data presented at the 2026 ASCO Annual Meeting.1 The...
Evolving Strategies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
When diffuse large B-cell lymphoma (DLBCL) fails to respond to front-line treatment or the disease later returns, Jeremy S. Abramson, MD, MMSc, wants to know when the disease progressed, if the patient is eligible for chimeric antigen receptor (CAR) T-cell therapy, and whether or not such treatment ...
FDA Approves Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer
On October 19, 2026, the U.S. Food and Drug Administration (FDA) granted an accelerated approval to the PD-1 inhibitor dostarlimab (Jemperli) for the treatment of adult patients with stage II/III locally advanced rectal cancer that is microsatellite instability–high (MSI-H) or mismatch repair...
Mocertatug Rezetecan Shows Early Activity in Platinum-Resistant Ovarian and Endometrial Cancers
First results from the global phase I BEHOLD-1 study suggest that the investigational B7-H4–targeted antibody-drug conjugate mocertatug rezetecan showed activity in two difficult-to-treat gynecologic cancers: platinum-resistant ovarian cancer and recurrent or advanced endometrial cancer.1 At the...
Immunotherapy-Based Downstaging Linked to Improved Outcomes After Liver Transplantation in Hepatocellular Carcinoma
An immune checkpoint inhibitor–based multimodal downstaging strategy before liver transplantation was associated with improved posttransplant survival and a lower risk of recurrence among patients with hepatocellular carcinoma initially beyond the Milan criteria (single lesion not larger than 5 cm...
Novel Androgen Receptor Degrader Demonstrates Antitumor Activity in Advanced Prostate Cancer
The novel androgen receptor degrader bavdegalutamide demonstrated a manageable safety profile and antitumor activity in patients with metastatic castration–resistant prostate cancer previously treated with androgen receptor pathway inhibitors, particularly those with tumors harboring specific...
Phase III VERIFY Trial Demonstrates Benefits of Rusfertide in Polycythemia Vera
According to findings from the phase III VERIFY trial reported by Kuykendall et al in the Journal of Clinical Oncology, the addition of the hepcidin mimetic rusfertide to standard-of-care therapy significantly improved hematocrit control, reduced the need for phlebotomy, and improved...
Iberdomide Triplet Improves MRD-Negative Complete Response in Relapsed/Refractory Multiple Myeloma
Iberdomide combined with daratumumab and dexamethasone nearly doubled the rate of minimal residual disease (MRD)-negative complete response compared with daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma. Lonial et al reported the primary MRD...
ASCO 2026: Lung Cancer Specialist Apar Kishor Ganti, MD, Shares His Insights
The 2026 ASCO Annual Meeting featured numerous high-impact studies in lung cancer. To help readers identify the presentations with the greatest potential to influence clinical practice, The ASCO Post asked lung cancer specialist Apar Kishor Ganti, MD, MS, FASCO, to share his top picks. Dr. Ganti is ...
Amyloidosis: Novel Treatments Could Improve Poor Outcomes
Systemic light chain amyloidosis is a clonal plasma cell disorder that can lead to end-organ dysfunction, with no approved treatment in the relapsed/refractory setting. Given this challenging clinical situation, two studies of novel therapies for this disease reported at the 2026 ASCO Annual...
Chronic Immune-Related Adverse Events Common After Adjuvant Anti–PD-1 Therapy for Melanoma
Nearly half of patients with resected high-risk melanoma treated with adjuvant anti–PD-1 therapy developed chronic immune-related adverse events, and more than one-third still had ongoing toxicity after a median follow-up of more than 5 years. Roma A. Kankaria, MD, and colleagues reported the...
FDA Approves Expanded Indication for Nogapendekin Alfa Inbakicept in BCG-Unresponsive NMIBC
On October 14, 2026, the U.S. Food and Drug Administration (FDA) approved the IL-15 receptor agonist nogapendekin alfa inbakicept-pmln (Anktiva) in combination with bacillus Calmette-Guérin (BCG) for the treatment of adults with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC). This...
Sitagliptin Added to Standard Prophylaxis Reduces Risk of Acute GVHD Following Alternative Donor Transplantation
Adding the selective, oral dipeptidyl peptidase-4 inhibitor, sitagliptin, to antithymocyte globulin–based prophylaxis significantly reduced the incidence of grade 2 to 4 acute graft-vs-host disease (GVHD) among patients undergoing alternative donor hematopoietic stem-cell transplantation, according ...
Implementing Massage and Acupuncture to Achieve Better Pain Management in Oncology Care: An Overview of the IMAGINE Project
Pain is an incredibly challenging symptom that affects over 40% of patients with cancer in active treatment1 and up to two in three patients with advanced cancer.2 Analgesic pain medications including opioids have been the predominant pain management strategy; however, their use is limited by...
Anitocabtagene Autoleucel Shows High Response Rate in Heavily Pretreated Relapsed/Refractory Multiple Myeloma
Anitocabtagene autoleucel (anito-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, produced responses in all treated patients in a phase I study of heavily pretreated relapsed or refractory multiple myeloma, with 79% achieving a...
HER2-Negative Advanced Gastric Cancers: First-Line Retlirafusp Alfa Combination Demonstrates Survival Benefit
The addition of retlirafusp alfa to capecitabine and oxaliplatin (CAPOX) significantly prolonged overall survival compared with chemotherapy alone as first-line treatment for patients with unresectable, locally advanced or metastatic, HER2-negative gastric or gastroesophageal junction...
FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon Cancer
On October 8, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients aged 2 years and older with stage III mismatch repair–deficient (dMMR) colon cancer. The FDA...
Starting Surveillance Colonoscopy After High-Risk Adenoma Removal: When Is the Right Time?
Surveillance colonoscopy at 5 years after removal of high-risk adenomas was noninferior to surveillance at 3 years in terms of colorectal cancer incidence during the first 5 years after adenoma removal, according to an interim analysis of the randomized EPoS II trial reported by Jover et al in The...
ACS Report Highlights Cancer Burden and Screening Disparities in U.S. Hispanic Population
The cancer distribution in the Hispanic population is distinct from the general population in the United States, according to a statistics report from the American Cancer Society (ACS) published in CA: A Cancer Journal for Clinicians. The report indicated fewer lung and urinary bladder cancers,...
The Molecular Watchman: Why Measurable Residual Disease Testing Is Redefining Treatment and Surveillance in Colorectal and Bladder Cancers
Implementing a personalized medicine approach in oncology increasingly includes the use of measurable residual disease (MRD) testing to detect molecular evidence of cancer that remains after treatment, enabling more precise risk stratification, earlier intervention, and more informed treatment...
Tile-Based Radiation Outperforms Postoperative Stereotactic Radiation Therapy in Resected Brain Metastases
According to findings from a phase III trial reported by Weinberg et al in the Journal of Clinical Oncology, intraoperative tile-based radiation therapy with cesium-131 significantly improved surgical bed control compared with postoperative stereotactic radiation therapy in patients undergoing...
Wildfire-Related Fine Particulate Matter Linked to Higher Mortality in Older Patients With Lung Cancer
Long-term exposure to fine particulate matter from wildfire smoke was associated with a higher risk of death among older patients with lung cancer, and wildfire-related particulate matter appeared more harmful than nonwildfire air pollution at the same exposure level. Zhang et al reported the...
FDA Approves First-Line Pirtobrutinib for CLL/SLL
On October 2, the U.S. Food and Drug Administration (FDA) approved pirtobrutinib (Jaypirca) for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion. Efficacy and Safety Efficacy was evaluated in the randomized,...
Pembrolizumab/Olaparib Strategy in BRCA-Nonmutated Advanced Ovarian Cancer
A pembrolizumab/olaparib strategy significantly improved progression-free survival in patients with newly diagnosed BRCA-nonmutated advanced epithelial ovarian cancer, although overall survival was not improved. Ignace Vergote, MD, PhD, and colleagues reported results from the phase III...
Are Narrower Negative Margins Linked to Higher Risk of DCIS Recurrence?
Among patients with ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery, negative surgical margins narrower than 2 mm were not associated with a significantly higher risk of ipsilateral recurrence compared with margins of at least 2 mm—except among patients younger than age...
Can Long Distance Running Be a Risk Factor for Early-Onset Colorectal Cancer?
Colorectal cancer, once thought of as mainly a disease of the aging, is rising in younger adults by nearly 3% per year and is now a leading cause of cancer-related death among individuals under the age of 50.1 According to the American Cancer Society, in 2026, nearly 159,000 individuals will be...
Multicancer Early Detection Screening Does Not Reduce Overall Late-Stage Cancer Diagnosis
The results of the randomized NHS-Galleri trial reported by Sasieni et al in The New England Journal of Medicine showed that annual screening with a blood-based multicancer early detection test added to usual care did not result in a significantly lower incidence rate of stage III or IV cancers...
NCCN Models How to Tailor Cancer Care for Different Regions During 2026 World Cancer Congress
The biennial World Cancer Congress, organized by the Union for International Cancer Control (UICC), is the leading international conference on cancer control, bringing together researchers, clinicians, advocates, policymakers, and people with lived experience from more than 120 countries. Two...
Depression Increases Cancer-Specific Mortality Risks in Common Cancers
Depression in patients with cancer may be associated with a higher mortality risk, according to findings from a large SEER-Medicare analysis presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 195). The analysis found that psychotherapy soon after...
Mindfulness and Tai Chi May Improve Symptoms After Cancer Treatment
Mindfulness-based cancer recovery and Tai Chi/Qigong were associated with improvements in fatigue and pain interference among distressed individuals who had completed cancer treatment, with Tai Chi/Qigong also improving sleep quality, according to findings from the Mindfulness and Tai Chi for...
Cancer Statistics 2026: Incidence, Mortality, Survival, and Disparities in U.S. Oncology
Cancer remains a dominant driver of morbidity and mortality globally and in the United States and continues to impose a substantial and evolving public health burden. Although age-adjusted cancer mortality has declined steadily for more than 3 decades, demographic aging and population growth have...
Short-Course SBRT Better Preserves Physical Function Before Pancreatic Cancer Surgery
Patients preparing for pancreatic cancer surgery maintained better physical function and experienced less fatigue with 5 treatments of stereotactic body radiation therapy (SBRT) than with 28 treatments of conventional radiation therapy given with chemotherapy, according to findings of a randomized...
Bivalent CAR T-Cell Therapy Shows No Delayed Toxicity and Promising Survival in Recurrent Glioblastoma
Longer follow-up from a phase I trial of intracerebroventricular bivalent CAR T-cell therapy in recurrent glioblastoma showed no long-term or delayed-onset toxicities, with a median overall survival of 12.0 months, according to updated data presented at the 2026 ASCO Annual Meeting. The...
Adding Targeted Immunotherapy to Pembrolizumab in Recurrent or Metastatic HPV16-Positive Head and Neck Squamous Cell Carcinoma
Based on the results of the nonrandomized multicenter phase II VERSATILE-002 trial reported in JAMA Oncology, a regimen adding the human papillomavirus type 16 (HPV16)-targeted immunotherapy PDS0101 to pembrolizumab demonstrated antitumor activity in immune checkpoint inhibitor–naive patients with...
SRS Is a "Reasonable Option" for Patients With SCLC and Brain Metastases
Stereotactic radiosurgery demonstrated a prolonged overall survival compared with hippocampal-avoidant whole-brain radiotherapy with memantine in patients with small cell lung cancer (SCLC) and brain metastases, according to phase III study findings presented at the 2026 American Society for...
Fractionated SRS Approach Improves Outcomes for Patients With Resected Large Brain Metastases
Fractionated stereotactic radiosurgery after resection improves surgical bed control compared with single-fraction stereotactic radiosurgery for patients with large brain metastases, according to findings from a phase III trial presented at the 2026 American Society for Radiation Oncology (ASTRO)...
Phase III Trial Compares HER2-Directed Antibody-Drug Conjugates in Advanced Breast Cancer
According to findings from a phase III randomized trial reported by Zhang et al in the Journal of Clinical Oncology, the novel HER2-directed antibody-drug conjugate trastuzumab botidotin significantly prolonged progression-free survival compared with ado-trastuzumab emtansine (T-DM1) in patients...
Building Momentum: ASCO’s Geriatric Oncology CoP
The ASCO Geriatric Oncology Community of Practice (geriatric oncology CoP) convened for its first in-person meeting at McCormick Place in Chicago in May 2026. Since its inception in 2022, the geriatric oncology CoP has brought together clinicians, researchers, trainees, and patient advocates...
Jonathan W. Goldman, MD, on SCLC: Tarlatamab Extended-Interval Dosing Regimens
Jonathan W. Goldman, MD, of the University of California, Los Angeles, reviews findings from the phase II DeLLphi-309 study, which examined the efficacy, safety, and pharmacokinetics of tarlatamab extended-interval dosing regimens (20 mg every 3 weeks and 30 mg every 4 weeks) in comparison to the...
Old Habits Die Hard: Project Optimus and the Next Generation of KRAS G12C Inhibitors
The recent announcement1 that divarasib, a next-generation KRAS G12C inhibitor, improved both progression-free and overall survival compared with first-generation KRAS G12C inhibitors (ie, sotorasib, adagrasib) is an important scientific milestone in the treatment of KRAS G12C–mutated non–small...
How One Nonprofit Is Providing Access to a Discontinued Investigational Drug for Children With a Rare Form of AML
Blood Cancer United (formerly the Leukemia & Lymphoma Society) recently announced it had acquired the remaining supply and rights to the investigational agent luveltamab tazevibulin, an antibody-drug conjugate targeting the folate receptor-1 alpha (FOLR1) molecule, from the drug’s manufacturer, ...
As AI Advances, How Will the Clinician’s Role Change?
Peter Clardy, MD, of Google for Health, described a fundamental challenge facing clinicians in the artificial intelligence (AI) era: AI capabilities are advancing rapidly at the same time clinicians are being asked to make decisions based on an ever-expanding volume of information. In oncology...
Daraxonrasib Shows Antitumor Activity in Previously Treated RAS-Mutant NSCLC
Daraxonrasib produced responses in more than 30% of patients with previously treated advanced RAS-mutant non–small cell lung cancer (NSCLC), with activity observed across multiple RAS mutations in a phase I/II study. Results from Kathryn C. Arbour, MD, David S. Hong, MD, and colleagues were...
Tambotatug Pelitecan May Improve Survival Outcomes in Relapsed SCLC
The B7-H3–targeting antibody-drug conjugate tambotatug pelitecan significantly improved overall survival compared with topotecan in patients with small cell lung cancer (SCLC) that had progressed after first-line platinum-based therapy, according to results of the phase III TAISHAN-302 trial...
